Israel’s Institute for Biological Research says it has successfully completed the first stage of its coronavirus vaccine and plans to expand its trials to some 1,000 volunteers for the next phase.
The first stage tested the Defense Ministry laboratory’s vaccine on 80 people out of Jerusalem’s Hadassah Hospitals and Ramat Gan’s Sheba Medical Center.
“During the first phase, no significant side effects were identified, and two expert committees, both internal and external, recommended the approval of the second phase. As such, the institute completed all the necessary preparations and is ready for the immediate launch of the second phase,” the Defense Ministry says.
Vials of a potential coronavirus vaccine are seen on an assembly line, in a photograph released by the Israel Institute for Biological Research on October 25, 2020. (Israel Defense Ministry)
The second phase of the clinical trials will begin in the coming days and will take place over several months, with approximately 1,000 volunteers taking part. This stage of the trial will again begin at the Sheba and Hadassah hospitals, but will gradually expand to other medical centers throughout the country.
“The scientists of the IIBR are Israel’s ‘elite unit,’ and have taken on an extremely important task — saving human lives. I see great importance in the development of an Israeli vaccine that will continue to serve Israeli society for years to come,” Defense Minister Benny Gantz says.
— Judah Ari Gross
We can't do this work alone.
The war with Iran has been draining for all of us in Israel. But when I heard about a high casualty incident – ballistic missile impacts in Arad and Dimona that left nearly 200 people wounded – I drank a cup of coffee, packed a bag, and headed south.
There, I spoke with Shilgit, the head of an after-school program for underprivileged youth. Standing outside her destroyed center, Shilgit said it was a miracle that no children were hurt and spoke about the community coming together in the hours since.
As a Times of Israel reporter, I’m committed to telling stories of resilience like Shilgit’s. But my colleagues and I can't do this alone. If you value work like this,please consider joining our reader support group, The Times of Israel Community. Your financial support is essential to keep real human reporting like this going.
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Thank you, David Horovitz, Founding Editor of The Times of Israel
From the Liveblog of
Monday, December 14, 2020
